MAPT and neurodegenerative disease: A recent publication showed that plasma p-tau217 discriminates clinically diagnosed AD from non-AD dementias with the same accuracy as CSF p-tau217 and tau PET imaging (all with AUCs > 0.95), and the levels in the plasma of p-tau217 are 5–7-fold increased in AD dementia compared to other neurodegenerative diseases [82].